Peptides DB
Research-centric peptide and protocol reference hub
Study 39 of 40VIP (Vasoactive Intestinal Polypeptide) literatureNeuropharmacology · Observational2026

Glycine transporter 1 inhibitor, bitopertin, changes excitatory and inhibitory network connectivity in mouse medial prefrontal cortex.

Bitopertin alters excitatory and inhibitory connectivity in the mouse mPFC, primarily impacting inhibitory interneurons without significantly inhibiting pyramidal neurons.

Read at NeuropharmacologyAdd to compare

Where it sits

this study against the rest of the vip (vasoactive intestinal polypeptide) corpus
8
Preclinical
25
Observational · this one
1
Open-label
2
Randomised
4
Reviews

Summary and findings

The study examined the effects of bitopertin, a GlyT1 inhibitor, on excitatory and inhibitory network connectivity in the medial prefrontal cortex of mice. It was found that bitopertin influenced NMDAR-mediated signaling in an IN-subtype-specific manner. Notably, bitopertin had no effect on the EPSC input strength of VIP-like interneurons but decreased their input probability and area.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Neuropharmacology supplied them

Cognitive deficits in Schizophrenia (SCZ) are correlated with excitation-inhibition (E/I) imbalance within the medial prefrontal cortex (mPFC). E/I imbalance may arise from N-methyl-D-aspartate receptor (NMDAR) hypofunction and dysfunction of GABAergic neurotransmission. Previous research has shown that bitopertin, a glycine transporter 1 (GlyT1) inhibitor, restores E/I balance. We investigated how GlyT1 inhibition affects NMDAR-mediated signaling and reshapes connectivity between excitatory and inhibitory neurons in the mPFC. We examined the effect of bitopertin on NMDAR-mediated transmission between pyramidal neurons (PNs) and inhibitory interneurons (INs), including putative vasoactive intestinal peptide-expressing (VIP-like), somatostatin-expressing (SST-like) and parvalbumin-expressing (PV) INs in the mouse mPFC. Our study utilized several complimentary techniques including channelrhodopsin-assisted circuit mapping, two-photon ex vivo functional imaging, brain slice electrophysiological recordings, and network modeling. Bitopertin influenced NMDAR-mediated excitatory drive in an IN-subtype-specific manner, via a non-presynaptic mechanism. Bitopertin had no effect on the EPSC input strength of VIP-like INs but decreased the input probability and area from which VIP-like INs received excitation. In contrast, Bitopertin strengthened excitatory synaptic connections to PV INs but had no effect on excitatory input area or probability. While increased excitation of inhibitory INs was expected to inhibit PN activity, our results showed no significant inhibition of PNs. This work uncovers the mode of action of bitopertin and the effects of GlyT1 inhibition on NMDA transmission within the mPFC network. Computational modeling suggests that these changes could contribute to partial normalization of network dynamics under simulated conditions of E/I imbalance mediated by NMDAR hypofunction. Together, we found that bitopertin chiefly impacts the inhibitory network, while minimally affecting PNs. This insight could aid the development of more effective therapies for cognitive dysfunctions caused by E/I imbalance.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the VIP (Vasoactive Intestinal Polypeptide) corpus

DClinical update: Assessment and management of Helicobacter pylori infection.BMJ (Clinical research ed.) · 2026reviewBComposite pheochromocytoma-ganglioneuroma secreting vasoactive intestinal peptide.Endocrinology, diabetes & metabolism case reports · 2026 · Maximal SUV of 14.4.HumanBOral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.Nature medicine · 2026HumanBVagal cholinergic denervation of the gastric mucosa in Long-COVID-19: In vivo evidence of structural autonomic dysfunction.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026 · 2.1 nm/µm³ vs 3.9 nm/µm³ in fundus, P < 0.01HumanCLiangfu Pill Alleviates Constipation-Predominant Irritable Bowel Syndrome through Modulation of 5-HT Signaling Pathway and Gut Microbiota.Chinese journal of integrative medicine · 2026 · P<0.05 or P<0.01 for various measured outcomes.AnimalBAtlas-Guided Cell-Specific Transcriptomics Identifies Pathway-Level Remodeling of Human Hypothalamic CRH Neurons in Opioid Use Disorderbiorxiv-preprint · 2026 · n=343819 · Nominal decrease in VIP, not quantified.Human